Rate My Professor Daniel Vatner

Dr. Vatner’s research explores insulin resistance in rodents and humans, focusing on its intersections with dyslipidemia, nonalcoholic fatty liver disease, thyromimetic development, lipoprotein lipase modulation, and glucocorticoid action. His investigations cover hepatic insulin resistance, adipose lipolysis, de novo lipogenesis, and metabolic dysfunction-associated steatohepatitis. Notable publications include “Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions” (Cell, 2023), “Rising NAFLD and metabolic severity during the Sars-CoV-2 pandemic among children with obesity in the United States” (Obesity, 2023), “Insulin increases placental triglyceride as a potential mechanism for fetal adiposity in maternal obesity” (Molecular Metabolism, 2022), “Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease” (Diabetes Care, 2020), “Altered Catecholamine Stimulated Adipose Lipolysis Contributes to Hepatic Steatosis in Pnpla3I148M Mice” (Cellular and Molecular Gastroenterology and Hepatology, 2025), “Elevation of hepatic de novo lipogenesis in mice with overnutrition is dependent on multiple substrates” (Journal of Lipid Research, 2025), “Altered Molecular Regulation of TUG Is a Central Feature of Insulin-Resistant Human Adipose Tissue” (Diabetes, 2025), “Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis” (Proceedings of the National Academy of Sciences, 2025), and “ATGL links insulin dysregulation to insulin resistance in adolescents with obesity and hepatosteatosis” (Journal of Clinical Investigation, 2025).